Sign In
Buy PACB
$1.15
-0.0350 (-2.95%)
At Close: Aug 10, 2026
Pacific Biosciences' Cost Cuts Won't Offset Rising Competition
03:38pm, Tuesday, 12'th Nov 2024
Pacific Biosciences of California stock surged 50% since August despite a 24% YoY revenue decline and deteriorating gross margins due to increased costs and pricing pressures. Q3 revenue of $40 millio
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:55am, Tuesday, 12'th Nov 2024
The rock star money manager is starting to roll with the rallying market.
PacBio price target lowered to $6 from $7 at Scotiabank
08:56am, Monday, 11'th Nov 2024
Scotiabank lowered the firm's price target on PacBio to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q3 update,
PacBio to Present at Upcoming Investor Conferences
04:05pm, Friday, 08'th Nov 2024
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be particip
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
11:10am, Friday, 08'th Nov 2024
PacBio Q3 2024 revenues decline year over year. However, Consumable, and Service and other revenues increase.
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
09:04pm, Thursday, 07'th Nov 2024
Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christian
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:31pm, Thursday, 07'th Nov 2024
The headline numbers for Pacific Biosciences (PACB) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
07:15pm, Thursday, 07'th Nov 2024
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share a year ago.
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
04:03pm, Thursday, 07'th Nov 2024
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priv
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
10:35pm, Wednesday, 06'th Nov 2024
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing
The Schall Law Firm Encourages Investors With Losses To Join An Inquiry Into Pacific Biosciences of California Inc For Fraud
11:00am, Monday, 04'th Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
The Schall Law Firm Encourages Investors To Join An Inquiry Into Pacific Biosciences of California Inc For Securities Fraud
11:00am, Saturday, 02'nd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosci
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
07:16pm, Thursday, 31'st Oct 2024
Pacific Biosciences of California (PACB) reachead $2.17 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep
10:13am, Wednesday, 30'th Oct 2024
BOSTON , Oct. 30, 2024 /PRNewswire/ -- Volta Labs™, a genomics applications company, announced today that it has joined the PacBio Compatible program, further expanding the partnership between Volt
